Alternatives to PAIN Act
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, Alternatives to PAIN Act, changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Finance, Agriculture.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H4CE1C0F4C5524720B2C462961D9D54D4: 1. Short title This Act may be cited as the Alternatives to Prevent Addiction In the Nation Act or the Alternatives to PAIN Act.
- Section H51C765457B134BFB9633179481F433D0: 2. Appropriate cost-sharing for qualifying non-opioid pain management drugs under Medicare part D Section 1860D–2 of the Social Security Act (42 U.S.C....
- Section HFD8EC2D08EC64693A3EFC81E94738572: 3. Prohibition on the use of step therapy and prior authorization for qualifying non-opioid pain management drugs under medicare part D Section 1860D–4(c) of...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, Alternatives to PAIN Act, changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Finance, Agriculture
Primary Purpose
This bill, Alternatives to PAIN Act, changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
In CommitteeMr. Tillis (for himself, Mr. Kelly, Mrs. Capito, Mr. Kaine, …
Read twice and referred to the Committee on Finance.
Introduced in Senate
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
Key Definitions
Terms defined in this bill
a drug or biological product—(i)that has a label indication approved by the Food and Drug Administration to reduce postoperative pain or any other form of acute pain
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology